Treatment of diabetes mellitus using an external insulin pump in clinical practice

Diabetes and Metabolism

Volumn 34, Issue 4 SUPPL. 1, 2008, Pages 425-438

  Jeandidier, N ^a   Riveline, J P ^b   Tubiana Rufi, N ^c   Vambergue, A ^d   Catargi, B ^e   Melki, V ^f   Charpentier, G ^b   Guerci, B ^g  

^a HÔPITAL CIVIL   (France)

^b Centre médicopédagogique de Corbeil Essonnes   (France)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f CHU RANGUEIL   (France)

^g Ctr Hospitalier Univ de Nancy   (France)

Author keywords

Devices; External insulin pump; flexible insulin therapy; Hyperglycaemia; Hypoglycaemia; Ketosis; Quality of life; Review; Self monitoring of blood glucose

Indexed keywords

GLUCOSE; GLULISIN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; UNCLASSIFIED DRUG;

ALGORITHM; ARTICLE; BEDTIME DOSAGE; BLOOD GLUCOSE MONITORING; BOLUS INJECTION; CARBOHYDRATE INTAKE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIABETES MELLITUS; DIETARY INTAKE; DOSAGE SCHEDULE COMPARISON; DOSE CALCULATION; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; EXERCISE; EXTERNAL INSULIN PUMP; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; KETOACIDOSIS; MEDICAL DECISION MAKING; MEDICAL TECHNOLOGY; PATIENT CARE; PATIENT EDUCATION; PATIENT PARTICIPATION; PEDIATRICS; PHARMACEUTICAL CARE; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREGNANCY; PROTEIN INTAKE; RECOMMENDED DRUG DOSE; SELF MONITORING; TREATMENT INDICATION;

BLOOD GLUCOSE; CHILD; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DRUG ADMINISTRATION SCHEDULE; EQUIPMENT DESIGN; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 54049150500     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(08)73973-9     Document Type: Article

References (46)

1. Bode B., Sabbah H., Gross T., Fredrickson L., and Davidson P. Diabetes management in the new millenium using insulin pump therapy. Diabetes Metab Res Rev 18 suppl 1 (2002) S14-S20
2. Guerci B., Hanaire H., Lassmann-Vague V., Leblanc H., Mihaelanu M., and Leutenegger E. Contexte et modalités de mise en route d'un traitement par pompe à insuline en milieu hospitalier : observatoire de l'insulinothérapie par pompe. Infusystems 23 (2006) 27-32
3. Standards of Medical Care in Diabetes-2008 American Diabetes Association Diabetes Care 2008 31:S12-S54.
4. Service F.J., and Nelson R.L. Characteristics of glycemic stability. Diabetes Care 3 (1980) 58-62
5. Guerci B., Jeandidier N., Lassmann-Vague V., Renard E., and Hanaire-Broutin H. Comment utiliser l'analogue de l'insuline lys-pro en perfusion sous-cutanée continue par pompe portable. Diabetes Metab 26 (2000) 513-519
6. Sachon C., Jacqueminet S., Hartemann-Heurtier A., and Grimaldi A. Should diabetic patients be asked to test their blood glucose 90 to 120 minutes after the beginning of their meals?. Diabetes Metab 32 (2006) 377-381
7. Guerci B., Tubiana-Rufi N., Bauduceau B., Bresson R., Cuperlier A., Delcroix C., et al. Advantages to using capillary blood beta-hydroxybutyrate determination for the detection and treatment of diabetic ketosis. Diabetes Metab 31 (2005) 401-406
8. Admon G., Weinstein Y., Falk B., Weintrob N., Benzaquen H., Ofan R., et al. Exercise with and without an insulin pump among children and adolescents with type 1 diabetes mellitus. Pediatrics 116 (2005) e348-e355
9. Tubiana-Rufi N., deLonlay P., Bloch J., and Czernichow P. Remission of severe hypoglycaemia incidents in young diabetic children treated with subcutaneous infusion. Arch Pediatr 3 (1996) 969-976
10. Conrad S.C., McGrath M.T., and Gitelman S.E. Transition from multiple daily injections to continuous subcutaneous insulin infusion in type 1 diabetes mellitus. J Pediatr 140 (2002) 235-240
11. Pickup J.C., Kidd J., Burmiston S., and Yemane N. Effectiveness of continuous subcutaneous insulin infusion in hypoglycaemia-prone type 1 diabetes: implications for NICE guidelines. Pract Diabet Int 22 (2005) 10-14
12. Pickup J., and Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 25 (2002) 593-598
13. Bode B.W., Steed R.D., and Davidson P.C. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care 19 (1996) 324-327
14. Boland E.A., Grey M., Oesterle A., Fredrickson L., and Tamborlane W.V. Continuous subcutaneous insulin infusion: a new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping inadolescents with type 1 diabetes. Diabetes Care 22 (1999) 1799-1884
15. Linkeschova R., Raoul M., Bott U., Berger M., and Spraul M. Less severe hypoglycaemia, better metabolic control, and improved quality of life in type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy: an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet Med 19 (2002) 746-751
16. Hanaire-Broutin H., Melki V., Bessierre-Lacombe S., and Tauber J.P. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment. Diabetes Care 23 (2000) 1232-1235
17. Selam J.L. Hypoglycémie et diabète insulino-dépendant. In: André G. (Ed). Traité de diabétologie (2005), Éditions Flammarion-médecine-science, Paris 214-226
18. Grimaldi A., Slama G., Tubiana-Rufi N., Heurtier A., Selam J.L., Scheen A., et al. L'hypoglycémie du patient diabétique. Diabetes Metab 23 (1997) 100-108
19. Zinmann B. Insulin pump therapy with subcutaneous insulin infusion and exercise in patients with type 1 diabetes. In: Ruderman N. Handbook of exercice in diabetes. Alexandria (Virginia). American Diabetes Association.
20. Diabetes Research in Children Network (DirecNet) Study Group. Prevention of hypoglycemia during exercise in children with type 1 diabetes by suspending basal insulin. Diabetes Care 29 (2006) 2200-2204
21. Valensi P. La neuropathie autonome diabétique : quels sont les risques ?. Diabetes Metab 24 Suppl 3 (1998) 66-72
22. Chase H.P., Saib S.Z., MacKenzie T., Hansen M.M., and Garg S.K. Post-prandial glucose excursions following four methods of bolus insulin administration in subjects with type 1 diabetes. Diabet Med 19 (2002) 317-321
23. Guerci B. Acute complications of insulin pump therapy. Diabetes Res Clin Pract 74 Suppl 2 (2006) S104-S107
24. Guerci B., Meyer L., Sallé A., Charrié A., Dousset B., Ziegler O., et al. Comparison of metabolic deterioration between insulin analog and 3_regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients. J Clin Endocrinol Metab 84 (1999) 2673-2678
25. Walter H., Gunther A., Timmler R., and Mehnert H. Ketoacidosen unter langzeittherapie mit insulinpumpen. Häufigkeit, ursachen, umstände Med Klin 15 (1989) 565-568
26. Peden N.R., Braaten J.T., and McKendry J.B. Diabetic ketoacidosis during long-term treatment with continuous subcutaneous insulin infusion. Diabetes Care 7 (1984) 1-5
27. Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS): communication sur le risque lié à un d'arrêt de perfusion lors d'un traitement par pompe à insuline externe. http://agmed.sante.gouv.fr/htm/10/dm/sdm/glycemie/risque_arret_pompe_insulin.pdf
28. Matta M.P., Melki V., Bessiere-Lacombe S., and Hanaire-Broutin H. What are capillary blood ketone levels in type 1 diabetic patients using CSII in normal conditions of insulin delivery?. Diabetes Metab 30 (2004) 543-547
29. Guerci B., Benichou M., Floriot M., Bohme P., Fougnot S., Franck P., et al. Accuracy of an electrochemical sensor for measuring capillary blood ketones by fingerstick samples during metabolic deterioration after continuous subcutaneous insulin infusion interruption in type 1 diabetic patients. Diabetes Care 26 (2003) 1137-1141
30. Laffel L. Sick-day management in type 1 diabetes. Endocrinol Metab Clin North Am 29 (2000) 707-723
31. Taboulet P., Haas L., Porcher R., Manamani J., Fontaine J.P., Feugeas J.P., et al. Urinary acetoacetate or capillary beta-hydroxybutyrate for the diagnosis of ketoacidosis in the Emergency Department setting. Eur J Emerg Med 11 (2004) 251-258
32. Taboulet P., Deconinck N., Thurel A., Haas L., Manamani J., Porcher R., et al. Correlation between urine ketones (acetoacetate) and capillary blood ketones (3-beta-hydroxybutyrate) in hyperglycaemic patients. Diabetes Metab 33 (2007) 135-139
33. Recommandations de bonnes pratiques, ALFEDIAM paramedical. Prise en charge des patients traités par pompes à insuline externe, portable et programmable (juin 2003 remis à jour mars 2007). http://www.alfediam.org/membres/recommandations/Pompes.pdf
34. Catargi B., Meyer L., Melki V., Renard E., Jeandidier N., and For the EVADIAC Study Group. Comparison of blood glucose stability and HbA1C between implantable insulin pumps using U400 HOE 21PH insulin and external pumps using lispro in type 1 diabetic patients: a pilot study. Diabetes Metab 28 (2002) 133-137
35. Howorka K., Pumprla J., and Schlusche C. Algorithm adaptation under functional insulin treatment during transfer from regular to insulin lispro. Diab Nutr Metab 11 (1998) 266-272
36. Franc S., Dardari D., Boucherie B., Hochberg G., Biedzinski M., Lejeune M., et al. Validation des paramètres de l'insulinothérapie fonctionnelle (IF) chez les diabétiques de type 1 dans la vie courante. Diabetes Metab 33 special issue 1 (2007) P171
37. Bode B.W., Tamborlane W.V., and Davidson P.C. Insulin pump therapy in the 21st century. Strategies for successful use in adults, adolescents, and children with diabetes. Postgrad Med 111 (2002) 69-77
38. Chantelau E., Sonnenberg G.E., Stanitzek-Schmidt I., Best F., Altenähr H., and Berger M. Diet liberalization and metabolic control in type 1 diabetic outpatients treated by continuous subcutaneous insulin infusion. Diabetes Care 5 (1982) 612-616
39. Lafrance L., Rabasa-Lhoret R., Poisson D., Ducros F., and Chiasson J.L. Effects of different glycaemic index foods and dietary fibre intake on glycaemic control in type 1 diabetic patients on intensive insulin therapy. Diabet Med 15 (1998) 972-978
40. Hunger-Dathe W., Braun A., Müller U.A., Schiel R., Femerling M., and Risse A. Insulin pump therapy in patients with Type 1 diabetes mellitus: results of the Nationwide Quality Circle in Germany (ASD) 1999-2000. Exp Clin Endocrinol Diabetes 111 (2003) 428-434
41. Alemzadeh R., Ellis J.N., Holzum M.K., Parton E.A., and Wyatt D.T. Beneficial effects of continuous subcutaneous insulin infusion and flexible multiple daily insulin regimen using insulin glargine in type 1 diabetes. Pediatrics 114 (2004) e91-e95
42. Laurent C. L'alimentation du diabétique traité par l'insuline. In: Dérot M. (Ed). Précis de diabétologie Ed (1977), Masson, Paris 833-847
43. Winiger G., Keller U., Laager R., Girard J., and Berger W. Protein content of the evening meal and nocturnal plasma glucose regulation in type-1 diabetic subjects. Horm Res 44 (1995) 101-104
44. Garg K., Rosenstock J., and Ways K. Optimized basal-bolus insulin regimens in type 1 diabetes: insulin Glulisine versus regular human insulin in combination with basal insulin Glargine. Endocrine Practice 11 (2005) 11-17
45. Pickup J.C., K45idd J., Burmiston S., and Yemane N. Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability. Diabetes Metab Res Rev 22 (2006) 232-237
46. Elgrably F., M'bemba J., Sola Gazagnes A., Rouxel A., Daenen S., Bruzzo F., et al. [Jeûne ambulatoire de 36 h pour la détermination des doses de base d'insuline avec auto-apprentissage intensifié ambulatoire : étude chez 27 patients diabétiques de type 1 sélectionnés]. Diabetes Metab 27 suppl 1 (2004) 13